VSValerii Shapovalov

Valerii Shapovalov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Valerii Shapovalov has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Concept 2035 Refresh 2027: Conceptual Architecture, Development from Working Draft v0.11 to v0.21, and an Implementation Agenda

    by Valentyn Shapovalov, Emma Nelson, Valerii Shapovalov, Viktoriia Shapovalova

    Concept 2035 began as a medico-pharmaceutical law framework for human security. Its ongoing Refresh 2027 develops that foundation into All-Being Security: a future-oriented architecture connecting human rights, artificial agency, possible artificial personhood, civilizational communication, demographic continuity, peace, institutional legitimacy, and responsible extraterrestrial advancement. This article presents the project's v0.21 snapshot and uses Working Drafts v0.11-v0.21 as a transparent development record. A normative conceptual synthesis examined seven issued drafts together with legal instruments, demographic evidence, artificial-intelligence governance literature, philosophical scholarship, peace research, language history, and space law. Claims were separated as descriptive, interpretive, normative, scenario-based, or speculative. The resulting framework preserves human rights as an immediately enforceable floor while making biological origin neither an automatic qualification nor a permanent disqualification for future moral or legal status. It defines All-Humanity as shared human responsibility without forced uniformity, and All-Being Concord as a higher-order test for decisions that affect multiple communities or possible forms of life. The framework further proposes an auxiliary Common All-Humanity Language, Population Continuity and Demographic Justice, safeguards against corporate enclosure and conflict incentives, pre-contact duties, staged extraterrestrial permissions, and prospective conditional collective title for apparently lifeless worlds. Education, voting, precaution, and law remain necessary but are treated as insufficient when agenda control, concentrated finance, institutional capture, or indefinite procedural delay defeats their purpose. The article concludes that the current Refresh 2027 architecture is a testable research programme rather than settled doctrine and should undergo a further documented update by 2027.


  • Psychoactive substance co-use, non-medical drug use and polypharmacy among Ukrainian outpatients: a brief report

    by Viktoriia Shapovalova, Alina Osyntseva, Valentyn Shapovalov, Valerii Shapovalov

    Harmful alcohol use and psychoactive substance use remain major global public health challenge. The World Health Organization (WHO) estimates more than 3 million deaths annually – about 5% of globa...


  • Open Access

    Medical Technologies. Pharmaceutical Cosmetology, Cosmeceuticals Based on Herbal Medicines: Modern Trends and Regulatory Approaches

    by Аліна Осинцева, Valerii Shapovalov, Valentyn Shapovalov, Alina Osyntseva

    Introduction. Modern cosmetology is characterized by the integration of medical technologies, pharmaceutical and cosmetic approaches, which led to the formation of cosmeceuticals as a separate direction. A special place in cosmeceuticals is occupied by phytopreparations that contain biologically active substances (flavonoids, carotenoids, triterpenoids) and provide a complex effect on the skin. Purpose of the study. To analyze the role of herbal remedies in cosmeceuticals on the example of Calendula officinalis L. (calendula extract), to conduct a comparative analysis with the requirements of Deutsches Arzneibuch (DAB), as well as to perform a SWOT (Strengths, Weaknesses, Opportunities, Threats)- and PESTEL (Political, Economic, Social, Technological, Environmental, Legal) analysis of the development of phytocosmeceuticals. Materials and methods. Documentary analysis of scientific sources and regulatory documentation, comparative analysis of pharmacopoeia requirements, pharmacological analysis of biologically active substances (quercetin, β-carotene, oleanolic acid derivatives), as well as SWOT and PESTEL analysis were used. Cosmeceutical preparations, in particular Calendula ointment (International Nonproprietary Name: Calendula extract) and dexpanthenol agents (chemical name: (R)-2,4-dihydroxy-N-(3-hydroxypropyl)-3,3-dimethylbutanamide) were studied. Results. It has been established that herbal remedies provide anti-inflammatory, antiseptic, antioxidant, and regenerative effects due to their multicomponent composition. Calendula extract has been shown to be effective in the treatment of inflammatory and degenerative skin conditions. It has been found that the requirements of DAB are more stringent and provide for standardization according to marker compounds and the use of chromatographic methods (TLC - (Thin-Layer Chromatography), HPLC (High-Performance Liquid Chromatography). SWOT analysis demonstrated the strengths of phytocosmeceuticals (naturalness, biocompatibility) and limitations (composition variability), while PESTEL analysis confirmed the significant impact of macroeconomic and regulatory factors on the development of the industry. Conclusions. Herbal remedies are a promising area of cosmeceuticals that combines effectiveness and safety. Calendula officinalis L. is one of the key ingredients in modern cosmeceuticals. It is necessary to improve the standardization system in accordance with European requirements and introduce innovative technologies to improve the quality of products.

  • Open Access

    Microbiome Therapies as an Emerging Therapeutic Approaches of Biomedicine: International Regulatory Approaches and Ethical Challenges

    by Valentyn Shapovalov, Viktoriia Shapovalova, Alina Osyntseva, Valerii Shapovalov

    Background: Microbiome-oriented therapies, including fecal microbiota transplantation (FMT), phage therapy, and live biotherapeutic products (LBPs), represent a promising direction in modern biomedicine for addressing antimicrobial resistance (AMR), recurrent Clostridioides difficile infection (rCDI), and dysbiosis-associated conditions. Despite encouraging clinical outcomes, their integration into routine clinical practice remains limited due to regulatory heterogeneity and unresolved ethical challenges. Objective: This review aims to analyze international regulatory approaches to microbiome-based therapies and to identify key bioethical issues associated with their clinical application. Main content: The paper summarizes current scientific evidence and regulatory frameworks governing microbiome therapies in the United States, the European Union, Ukraine, and selected Asia-Pacific countries. Particular attention is given to differences in classification, approval pathways, and safety requirements. The review also examines major ethical concerns, including informed consent, donor screening, biosafety, data protection, and equitable access to innovative treatments. Conclusions: The analysis demonstrates that microbiome therapies have significant potential for improving clinical outcomes and supporting antimicrobial stewardship. However, their broader implementation requires the harmonization of regulatory frameworks, strengthening of biosafety standards, and development of clear ethical guidelines. International cooperation and accumulation of clinical evidence are essential for the safe and effective integration of microbiome-based interventions into healthcare systems.


  • Open Access

    Differential Diagnostic and Therapeutic Tactics of Pleurisy in Pancreatitis and Hepatitis: ABC and ABC/VED Analysis of Pathogenetic Pharmacotherapy

    by Oleksandr Nevzghoda, Ihor Haiduchok, Valerii Shapovalov

    Introduction. Pleurisy associated with pancreatitis and liver diseases is accompanied by malabsorption and deficiency of fat-soluble vitamins, which justifies the use of vitamin pathogenetic pharmacotherapy. At the same time, the structure of the pharmaceutical market of vitamin drugs may not meet real clinical needs, which requires pharmacoeconomic assessment. Purpose. Clinical and pharmaceutical justification of the use of vitamin pharmacotherapy in patients with exudative pleurisy on the background of pancreatitis and hepatitis based on the analysis of the frequency of prescriptions and integrated ABC/VED-analysis of the range of drugs. Materials and methods. A retrospective observational study of 398 patients with exudative pleurisy who underwent inpatient treatment was conducted. The frequency of prescribing vitamin A, vitamin D, vitamin E and vitamin K as part of complex pharmacotherapy was analyzed. The pharmaceutical analysis included a study of the range of vitamin drugs registered in Ukraine using structural ABC analysis, clinically oriented ABC analysis by frequency of prescriptions and VED classification. Results. Established that the range of fat-soluble vitamins is represented by 19 drugs, among which vitamin E drugs dominate (68.42% of positions). Clinical analysis showed that vitamin E was the most frequently prescribed active pharmaceutical ingredient in patients with pancreatogenic and hepatogenic pleurisy. Integrated ABC/VED analysis identified vitamin E drugs as the priority category AV, while vitamin D and vitamin A formed the BE group, and vitamin K - the CD group. A discrepancy between the structure of the pharmaceutical market and the real clinical need was revealed, which indicates the duplication of trade names of vitamin E preparations.

  • Open Access

    Criminal Law Level of Drug Trafficking, Forensic Pharmaceutical, Forensic Narcological Study of the Degree of Drug Addiction Prevention in Ukraine: Using a Large American Initiative to Recover Addiction to Psychoactive Substances

    by Valerii Shapovalov

    Illicit trafficking in narcotic drugs, psychotropic substances and other psychoactive substances is an urgent problem of public health, social security, and criminal law policy of each state. The current situation necessitates a comprehensive combination of prevention of disorders associated with the use of psychoactive substances, timely detection and treatment, rehabilitation, and social reintegration of persons with addiction with effective measures of criminal law counteraction to drug trafficking. Of particular importance for Ukraine is the study of international experience, in particular modern approaches of the United States to combating illicit trafficking in psychoactive substances, the organization and financing of long-term recovery programs. The study is based on the analysis of international documents in the field of drug control, regulations of Ukraine, scientific publications, materials on drug policy of the United States and EU countries, as well as examples of criminal law, forensic pharmaceutical and law enforcement practice in Ukraine in 2025-2026. Methods of systemic, comparative legal, structural-functional, and interdisciplinary analysis are used. Modern drug business acquires signs of transnational organized crime, actively uses digital technologies, the Internet, instant messengers, cryptocurrency, and complex financial and logistical mechanisms. The analysis of criminal law and forensic pharmaceutical practice has shown the need to strengthen interagency cooperation between law enforcement agencies, prosecutors, courts, lawyers, and experts, as well as the development of forensic pharmaceutical, forensic narcology, forensic psychiatric, forensic medical and forensic examination. The expediency of an integrated approach that combines primary, secondary, and tertiary prevention, early detection, treatment, rehabilitation, and social reintegration of persons with disorders associated with the use of psychoactive substances has been substantiated. Generalization of the US experience showed the importance of simultaneous influence on drug trafficking, its financial basis and demand for psychoactive substances, as well as the development of long-term recovery programs. Countering drug trafficking in Ukraine requires a transition from a predominantly repressive approach to a comprehensive interdisciplinary model that integrates criminal, forensic, medical, pharmaceutical, narcology, social and preventive measures. Promising areas are the deepening of cooperation between Ukraine and the United States and the EU countries, the improvement of mechanisms for early detection and treatment of addictions, the provision of rehabilitation and social reintegration, as well as the regulatory expansion of access of patients with disorders related to the use of psychoactive substances to free or preferential drug provision by making appropriate amendments to the Resolution of the Cabinet of Ministers of Ukraine dated August 17, 1998 No. 1303.

  • Open Access

    Tuberculous Pleural Disease (Pleuritis, Empyema): Clinical Perspective on First-Line Antituberculosis Medicines and Manufacturer-Based Content Analysis

    by V.O. Shapovalova, O.A. Nevzghoda, V.V. Shapovalov, A.O. Osyntseva

    Tuberculous pleural lesions (exudative pleurisy, tuberculous empyema) remain an urgent clinical and social problem, especially in conditions of high comorbidity, consequences of COVID-19, migration processes, hostilities, and disruption of the organisation of drug supplies. Despite the effectiveness of first-line antituberculosis medi­cines (isoniazid, rifampicin, pyrazinamide, ethambutol), the effectiveness of treatment of pleural forms is determined not only by the pharmacological properties of drugs, but also by their availability, the availability of appropriate dosages, fixed combinations, paediatric forms and confirmed production quality. Most clinical guide­lines are based on data on pulmonary forms of tuberculosis, which leads to a lack of direct evidence for pleural localisations and emphasises the importance of a structured analysis of the range of drugs by manufacturer. Objective — based on the modern evidence base, evaluate the clinical perspective and perform a manufacturer-oriented content analysis of the first-line antituberculosis medicines assortment (dosage forms, dosages, fixed combinations, registration status) for tuberculous pleural lesions (pleurisy, empyema), considering the effective­ness, safety, availability and continuity of treatment. Offer practical recommendations for clinicians (phthisiat­rician, pulmonologist, family doctor), clinical pharmacist, healthcare manager, administration of the institution, protocol and formulary commission. Materials and methods. A manufacturer-oriented content analysis of first-line antituberculosis medicines registered and approved for medical use in Ukraine in 2023—2025 was carried out. Data from international and national clinical guidelines (World Health Organization, American Thoracic Society, Centers for Disease Cont­rol and Prevention, European Respiratory Society, Infectious Diseases Society of America, standards of the Ministry of Health of Ukraine), registration dossiers, official instructions for medical use and the State Register of Medicines were used. Good Manufacturing Practice (GMP) compliance, inclusion in national evidentiary documents, compliance with international recommendations were assessed. The grouping of drugs by manufacturers was carried out according to the Sturges’ formula; dosage forms, dosages, fixed-dose combinations, pediatric suitability and the availability of bioequivalence data were evaluated separately. Results and discussion. A full range of dosage forms and dosages of first-line antituberculosis medicines necessary for the implementation of standard treatment regimens for pleural forms of tuberculosis has been identified. Differences between manufacturers in the presence of fixed combinations, low-dose and paediatric forms have been established, which determines the different level of their clinical suitability. The significance of penetration of drugs into the pleural space and the risks of subtherapeutic concentrations of rifampicin and pyrazinamide have been shown, which emphasise the importance of observing full-fledged regimens without interruption. Algorithms for the correction of adverse reactions, concomitant therapy and principles of intensive and continuation phases are analysed. Four groups of manufacturers were formed according to a comprehensive assessment of quality, availability, and stability of supply. An assortment of 41 drugs relevant for different patient categories, including children, has been identified. Gaps in fixed combinations and certain dosages have been identified, which require formulary and logistical solutions. Conclusions. Manufacturer-oriented content analysis is an effective tool for optimising the pharmacotherapy of tuberculous pleural lesions, providing a structured assessment of the range of first-line antituberculosis medicines in terms of effectiveness, safety, availability of dosages and quality of production. The results obtained make it possible to form reasonable recommendations for TB doctors, clinical pharmacists, formulary and procurement commissions, considering the need for continuity of treatment, minimisation of risks of resistance and increased patient adherence. The study highlights the need for further clinical work aimed at optimising treatment regimens specifically for pleural forms of tuberculosis and the introduction of Therapeutic Drug Monitoring in at-risk groups.


  • Open Access

    МЕДИЧНЕ ТА ФАРМАЦЕВТИЧНЕ ПРАВО, ЯК ДЖЕРЕЛО ВИВЧЕННЯ НАВЧАЛЬНОЇ ДИСЦИПЛІНИ «ОСНОВИ МЕДИЧНИХ ЗНАНЬ», СУДОВО-ФАРМАЦЕВТИЧНИХ, СУДОВО-МЕДИЧНИХ І СОЦІАЛЬНО-ЕКОНОМІЧНИХ РИЗИКІВ ЩОДО ВИГОРАННЯ МЕДИКІВ ЗАДЛЯ ВИКЛЮЧЕННЯ ЗЛОЧИНІВ В ЗАКЛАДАХ ОХОРОНИ ЗДОРОВ’Я

    by Ігор Гайдучок, Ольга Рябуха, Василь Попович, Аліна Циснецька, Альона Ковпак, Олександр Вейц, Галина Закалик, Наталія Шувар, Наталія Мацко, Валерій Шаповалов

    Вигорання працівників охорони здоров’я є актуальною міждисциплінарною проблемою, що потребує системного реагування на рівні держави, органів місцевого самоврядування та закладів охорони здоров’я. У статті наголошено на позиції ВООЗ щодо необхідності захисту здоров’я, безпеки та благополуччя медичних, фармацевтичних і доглядових працівників у межах Глобального плану дій з безпеки пацієнтів на 2021-2030 роки. Обґрунтовано значення клінічного маршруту пацієнта як структурованого мультидисциплінарного інструмента, що забезпечує стандартизацію лікувального процесу, оптимізацію медичної та реабілітаційної допомоги, зменшення дублювання обстежень і підвищення прозорості, безпечності та доступності медичної допомоги. Підкреслено доцільність залучення штучного інтелекту на всіх етапах маршруту пацієнта у системі «лікарня–відділення–лікар». Показано, що надмірне покладання обов’язків на лікаря без належної участі інших працівників закладу створює передумови для професійного вигорання та підвищує ризики неналежного виконання професійних обов’язків. Натомість дотримання клінічних протоколів і стандартів медичної допомоги, основаних на доказовій медицині та доказовій фармації, є важливою умовою зниження професійних ризиків і підвищення якості допомоги. Подано вивчення Програми для навчальної дисципліни «Основи медичних знань», розробленої для підготування здобувачів освіти спеціальності I7 «Терапія та реабілітація» бакалаврського рівня вищої освіти. Її опанування сприяє формуванню медичної, правової та професійної культури, розвитку клінічного мислення й профілактиці професійного вигорання у майбутніх працівників сфери охорони здоров’я, професіоналів та фахівців.


  • Open Access

    Medical And Pharmaceutical Law and US Anti-Corruption Approaches: Application to the Ukrainian Healthcare System (Patient-Oriented Aspect)

    by Olena Lavoshnyk, Gennady Georgievsky, Valerii Shapovalov

    The article is devoted to the analysis of corruption manifestations in the field of health care in Ukraine from the standpoint of medical and pharmaceutical law, as well as the experience of the United States of America within the framework of the program "America is Back", aimed at strengthening the patient-oriented approach. Modern trends in reforming the US health care system, mechanisms for preventing fraud, abuse and misuse of funds in medical institutions are considered. A comparative analysis of the practices of the United States and Ukraine regarding fight against corruption in the field of medicine, specific examples from forensic pharmaceutical practice are given, which demonstrate the systemic nature of problems in the domestic health care system. The role of the National Health Service of Ukraine, the Ministry of Health, the State Audit Service and law enforcement agencies in identifying violations, abuses and misuse of budget funds is shown. The need to improve the skills of medical and pharmaceutical workers in the field of medical and pharmaceutical law, to ensure the transparency of financial transactions and to strengthen the personal responsibility of the heads of medical institutions has been substantiated. It is proposed to introduce effective mechanisms of control, unification of the regulatory framework and monitoring to minimize corruption risks and build citizens' trust in the medical system of Ukraine.